<DOC>
	<DOC>NCT01792583</DOC>
	<brief_summary>The primary objective of the Nuvigil/Provigil Pregnancy Registry is to characterize the pregnancy and fetal outcomes associated with Nuvigil and Provigil exposure during pregnancy.</brief_summary>
	<brief_title>The Nuvigil and Provigil Pregnancy Registry</brief_title>
	<detailed_description />
	<mesh_term>Sleep Apnea, Obstructive</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Sleep Disorders, Circadian Rhythm</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Reported exposure to Nuvigil (armodafinil) and/or brand or generic formulations of Provigil (modafinil) within 6 weeks of becoming pregnant, or during pregnancy Able and willing to provide informed consent Able and willing to provide healthcare professional and secondary contact information, and for the patient herself to be contacted periodically by Registry staff Patients who refuse to provide oral or written informed consent Patients not exposed to armodafinil or brand or generic formulation of modafinil Pregnancy from outside the United States</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>pregnancy</keyword>
</DOC>